For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

The treatment of multiple myeloma is considered a continuously evolving paradigm as a
result of the growing availability of new and highly effective drugs, including first-and second …

For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy.
In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide …

Preclinical data suggest that combining a checkpoint inhibition with immunomodulatory
derivative can increase anticancer response. We designed a dose-escalation study using a …

Background Patients with adult T-cell leukaemia-lymphoma have few treatment options after
relapse and poor survival outcomes with current therapies. We aimed to determine the …

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and
clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the …

Lenalidomide (LEN) is an immunomodulatory drug with US Food and Drug Administration
approval for use in myelodysplastic syndromes (MDS), multiple myeloma (MM), and mantle …

Abstract Purpose of Review The purpose of this review was to evaluate management
strategies for common adverse effects of novel therapies in multiple myeloma (MM) …

The article presents case studies of five patients with multiple myeloma including a 60-year-
old male with a history of rheumatoid arthritis, a 71-year-old male with anaemia and a 61 …

Immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide, are widely used
treatments for multiple myeloma; however, they occasionally lead to episodes of itchy skin …